Research programme: antibacterials - MerLion Pharmaceuticals

Drug Profile

Research programme: antibacterials - MerLion Pharmaceuticals

Alternative Names: Anti-virulence programme - MerLion; Hybrid programme - MerLion; Lipopeptide antibacterials - MerLion

Latest Information Update: 18 Jan 2011

Price : $50

At a glance

  • Originator Combinature Biopharm
  • Class Aminoglycosides; Lipoproteins; Macrolides; Oligosaccharides; Xanthenes
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Bacterial infections

Most Recent Events

  • 18 Jan 2011 Preclinical development is ongoing in Germany
  • 21 Aug 2006 Combinature Biopharm has been acquired by MerLion Pharmaceuticals
  • 12 Apr 2005 Preclinical trials in Bacterial infections in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top